Orchestra BioMed Holdings, Inc. Ordinary Shares (OBIO) Stock
Fundamentals
Recent news

Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?
Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?
OBIO

These Two Healthcare Stocks Hit Key Milestones Today – Why Is Wall Street Bullish On Them?
These Two Healthcare Stocks Hit Key Milestones Today – Why Is Wall Street Bullish On Them?
OBIO

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Misses Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Misses Revenue Estimates
OBIO
Technicals
Analyst Ratings
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
% positive news of 3 articles
published over the past 14 days
Latest news

Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?
Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?
OBIO

These Two Healthcare Stocks Hit Key Milestones Today – Why Is Wall Street Bullish On Them?
These Two Healthcare Stocks Hit Key Milestones Today – Why Is Wall Street Bullish On Them?
OBIO

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Misses Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Misses Revenue Estimates
OBIO
About Orchestra BioMed Holdings, Inc. Ordinary Shares
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. David P. Hochman | Founder, Chairman of the Board of Directors & CEO | 1975 |
| Mr. Darren R. Sherman | Founder, President, COO & Director | 1971 |
| Mr. Andrew Lawrence Taylor M.B.A. | Chief Financial Officer | 1971 |
| Mr. William Reed Little | Executive Vice President of Corporate Development & Strategy | 1971 |
| Ms. Lisa Daniels | Vice President of Human Resources | — |
| Dr. Yuval Hay Mika D.Sc, Ph.D. | GM & CTO of Bioelectronic Therapies | 1959 |
| Dr. Hans-Peter Stoll M.D., Ph.D. | Senior VP & Medical Director | — |
| Dr. Avraham Matityahu Fischer M.D. | Senior Vice President of Medical Affairs & Innovation | 1956 |
| Mr. Bob Laughner | Senior Vice President of Regulatory & Quality | — |
| Mr. Juan Lorenzo | Senior Vice President of Product Development | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
3 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +8.5 | -7.4 | +22.3 | +21.4 |



